Capital Fund Management (CFM)
IOVA icon

Capital Fund Management (CFM)’s Iovance Biotherapeutics IOVA Stock Holding History

Capital Fund Management (CFM)’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-181,074
Closed -$494K – 2309
2025
Q4 		$494K Sell
181,074
-120,004
-40% -$278K ﹤0.01% 2221
2025
Q3 		$653K Sell
301,078
-73,835
-20% -$174K ﹤0.01% 2238
2025
Q2 		$645K Sell
374,913
-224,958
-38% -$560K ﹤0.01% 2139
2025
Q1 		$2M Buy
599,871
+409,688
+215% +$2.11M 0.01% 1420
2024
Q4 		$1.41M Sell
190,183
-224,490
-54% -$2.08M ﹤0.01% 1644
2024
Q3 		$3.89M Buy
414,673
+31,413
+8% +$298K 0.01% 1140
2024
Q2 		$3.07M Buy
+383,260
New +$4.11M 0.01% 1191
2023
Q4 		– Sell
-219,973
Closed -$1M – 2205
2023
Q3 		$1M Sell
219,973
-52,657
-19% -$344K ﹤0.01% 1646
2023
Q2 		$1.92M Sell
272,630
-162,616
-37% -$1.16M 0.01% 1203
2023
Q1 		$2.66M Sell
435,246
-102,496
-19% -$707K 0.01% 969
2022
Q4 		$3.44M Buy
537,742
+437,434
+436% +$3.42M 0.02% 760
2022
Q3 		$961K Buy
+100,308
New +$1.16M 0.01% 1102

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Capital Fund Management (CFM)'s IOVA Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 181,074 shares — an estimated $494K sold.

Capital Fund Management (CFM) first reported a position in IOVA in Q3 2022 and held it in 12 quarters. The position peaked at $3.89M in Q3 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Capital Fund Management (CFM) reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 181,074 Iovance Biotherapeutics shares in Q1 2026, an estimated $494K.
  • Capital Fund Management (CFM) first reported a position in Iovance Biotherapeutics in Q3 2022 and held it in 12 quarters.
  • Capital Fund Management (CFM)'s Iovance Biotherapeutics position peaked at $3.89M in Q3 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.